title: [Expression of basic fibroblast growth factor and nuclear factor-kappaB and the effect of budesonide on their expression in rats with asthma].
abstract: OBJECTIVE
  To study the expression of basic fibroblast growth factor (b-FGF) and nuclear factor-kappaB (NF-kappaB) in the airway and the effect of budesonide on their expression in rats with asthma.
  
  
  METHODS
  Forty-five Sprague-Dawley male rats were randomly divided into three group: placebo control, untreated asthma, and budesonide-treated asthma. Asthma was induced by intraperitoneal injection of 10% ovalbumin (OVA) on days 1 and 8 and then challenged by inhalation of 1% OVA aerosol. The budesonide-treated asthma group received an inhalation of budesonide (1 mg) 30 minutes after OVA challenge. The pathological changes of the airway were assessed, and the expression of b-FGF and NF-kappaB in the airway was assayed by hematoxylin and eosin staining and immunohistochemistry.
  
  
  RESULTS
  Budesonide treatment alleviated airway injuries. Compared with the control group, b-FGF and NF-kappaB expression in the airway in the untreated asthma group increased significantly (P< 0.05). The budesonide-treated asthma group demonstrated significantly decreased b-FGF (111.61+/- 5.52 vs 126.21+/- 6.46; P< 0.05) and NF-kappaB expression (110.65+/- 8.71 vs 134.15+/- 9.42; P< 0.05) in the airway as compared with the untreated asthma group. B-FGF expression was positively correlated to NF-kappaB expression in the budesonide-treated group.
  
  
  CONCLUSIONS
  b-FGF and NF-kappaB may be associated with airway remodeling in rats with asthma. Budesonide can improve airway remodeling, possibly by decreasing the expression of b-FGF and NF-kappaB.
authors.affiliation: Department of Pediatrics, Third Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
authors.forename: Chun-Xia
authors.initials: CX
authors.lastname: Cang
authors.forename: Bin
authors.initials: B
authors.lastname: Luan
mesh_terms: D000818:Animals; D001249:Asthma / Q000378:metabolism* / Q000473:pathology; D001980:Bronchi / Q000187:drug effects / Q000473:pathology; D019819:Budesonide / Q000494:pharmacology*; D016222:Fibroblast Growth Factor 2 / Q000032:analysis*; D007150:Immunohistochemistry; D008297:Male; D016328:NF-kappa B / Q000032:analysis*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D016328:NF-kappa B; D016222:Fibroblast Growth Factor 2; D019819:Budesonide